Daliresp and Gait deviation - a phase IV clinical study of FDA data
Summary:
We study 4,858 people who take Daliresp (roflumilast) or have Gait deviation. No report of Gait deviation is found in people who take Daliresp.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
What is Daliresp?
Daliresp has active ingredients of roflumilast. It is often used in chronic obstructive pulmonary disease. eHealthMe is studying from 4,722 Daliresp users. Check the latest studies of Daliresp.
What is Gait Deviation?
Gait deviation is found to be associated with 8 drugs and 153 conditions by eHealthMe. Check the latest studies of Gait deviation.
No report is found.
Do you take Daliresp and have Gait deviation?
- Check whether Gait deviation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Daliresp:
- Daliresp (4,722 reports)
Gait deviation treatments and more:
- Gait deviation (136 reports)
How severe was Gait deviation and when was it recovered:
Expand to all the drugs that have ingredients of roflumilast:
Browse all side effects of Daliresp:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Gait deviation:
Browse all the conditions that are associated with Gait deviation:
Drugs similar to Daliresp and Gait deviation :
How the study uses the data?
The study uses data from the FDA. It is based on roflumilast (the active ingredients of Daliresp) and Daliresp (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Evista cause Coordination Abnormal? - 3 seconds ago
- Could Propofol cause Hoarseness Or Changing Voice? - 7 seconds ago
- Drug interactions of Pravachol and Macrodantin - 16 seconds ago
- Could Vitamin B12 cause Nail Dystrophy? - 29 seconds ago
- Could Coq cause Knee Joint Replacement? - 45 seconds ago
- Drug interactions of Vumerity and Glipizide - 55 seconds ago
- Could Vpriv cause Abdominal Pain Upper? - a minute ago
- Anzemet and Stress And Anxiety for Men aged 50-59 - a minute ago
- Anzemet and Anxiolytic Therapy for Men aged 50-59 - a minute ago
- Anzemet and Anxiety And Stress for Men aged 50-59 - a minute ago